

(<http://blog.pharmacist.com>)

[Home](#) > Osimertinib approved as first-line treatment for EGFR-mutated non-small cell lung cancer

---

**Generic Name:**

Osimertinib

**Trade Name:**

Tagrisso

**Company:**

AstraZeneca

**Notes:**

AstraZeneca announced FDA approval of [osimertinib](#) for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations (exon 19 deletions, or exon 21 L858R mutations), as detected by an FDA-approved test.

Approval was based on results from the Phase III FLAURA trial, which compared osimertinib to current first-line EGFR tyrosine kinase inhibitors, erlotinib or gefitinib, in previously untreated patients with locally advanced or metastatic EGFR-mutated (EGFRm) NSCLC. The agent met the primary endpoint of progression-free survival.

The agent was previously approved for second-line treatment of patients with metastatic EGFRm NSCLC whose disease has progressed on or after a first-line EGFR-TKI therapy and who have developed the secondary T790M mutation, as detected by an FDA-approved test.

**Medication Monitor Categories:**

[Supplemental Approvals](#)

---

**Source URL:** <http://blog.pharmacist.com/supplemental-approvals/osimertinib-approved-first-line-treatment-egfr-mutated-non-small-cell-lung>